Newsfile Corp
24 Jun 2026, 20:35 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a securities class action lawsuit alleging the use of channel stuffing to inflate revenue. — Allegations of revenue manipulation through channel stuffing are severe and typically lead to downward revisions of financial trust and stock price.
-0.70The lawsuit claims ADMA Biologics engaged in undisclosed related party transactions and lacked adequate internal controls. — Poor internal controls and undisclosed conflicts of interest signal governance risks that can alienate institutional investors.
-0.50The lead plaintiff deadline for the ADMA Biologics securities class action is August 10, 2026. — This is a procedural deadline that confirms the litigation is active, though it does not provide new fundamental data.
-0.10Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a securities class action lawsuit alleging channel stuffing and misleading statements.
The company is the subject of a securities class action lawsuit.
The company is the subject of a securities class action lawsuit regarding investor losses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
3h ago
